RAD52 has already shown promise as a drug target. Inhibitors of the protein can selectively kill cancerous cells while ...

A new research paper was published in Oncotarget, Volume 16, on March 27, 2025, titled "Imipridones ONC201/ONC206 + RT/TMZ ...

Richardson, has published promising findings from the past seven years of research into a new approach for the treatment of ...

FDA grants orphan drug designation to HLX22 for gastric cancer, with a phase 2 trial showing improved progression-free ...

EVM14 received FDA clearance for clinical trials, marking Everest Medicines’ first in-house developed therapeutic to reach ...

A new drug is showing promise in tackling treatment-resistant ovarian cancer. Relacorilant, the drug tested in a phase 3 ROSELLA trial with Corcept Therapeutics in California, was found to improve ...

Recent breakthroughs by The Institute of Cancer Research in London and the University of Virginia in the U.S. could cut drug ...

Results from a new Phase 3 trial published in the journal npj Precision Oncology found that a cancer stem cell test can ...

Recent innovations include engineering CAR T-cells to overcome the immunosuppressive tumour microenvironment and enhancing ...

A new research paper was published in Oncotarget, Volume 16, on March 21, 2025, titled “NSD2-epigenomic reprogramming and ...